Cargando…

When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y(12) Inhibition Induced by Ticagrelor

Detalles Bibliográficos
Autores principales:	Capodanno, Davide, Angiolillo, Dominick J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955356/ https://www.ncbi.nlm.nih.gov/pubmed/33302757 http://dx.doi.org/10.1161/JAHA.120.019432

Ejemplares similares

Platelet thrombin receptor antagonism and atherothrombosis
por: Angiolillo, Dominick J., et al.
Publicado: (2010)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
por: Åstrand, Magnus, et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of CSL112
por: Ortega-Paz, Luis, et al.
Publicado: (2023)

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2013)

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
por: Angiolillo, Dominick J., et al.
Publicado: (2021)

When Less Is More: Losing Genes on the Path to Becoming Human
por: Gross, Liza
Publicado: (2006)

A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease
por: Price, Matthew J., et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2022)

Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor
por: Costa, Thiago Guarato Rodrigues, et al.
Publicado: (2022)

Recovery Time of Platelet Function After Aspirin Withdrawal
por: Lee, Jeonghun, et al.
Publicado: (2014)

Ticagrelor – toward more efficient platelet inhibition and beyond
por: Kubisa, Michał J, et al.
Publicado: (2018)

Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor
por: Lieder, Helmut Raphael, et al.
Publicado: (2022)

Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting
por: Buccheri, Sergio, et al.
Publicado: (2019)

Long-term monotherapy with ticagrelor after coronary stenting: the GLOBAL LEADERS study
por: Greco, Antonio, et al.
Publicado: (2020)

Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment
por: Joo, Hyung Joon, et al.
Publicado: (2018)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
por: Teng, Renli
Publicado: (2015)

Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety
por: Dobesh, Paul P, et al.
Publicado: (2014)

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
por: Ma, Tingting, et al.
Publicado: (2022)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2022)

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
por: Sweeny, Joseph M., et al.
Publicado: (2017)

Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management
por: Ortega‐Paz, Luis, et al.
Publicado: (2021)

Therefore, When I Grow Up I Want to Become an Aspirin Tablet
por: Myles, Ian A.
Publicado: (2018)

Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers
por: Traby, Ludwig, et al.
Publicado: (2019)

Commentary: When is less more?
por: Sinha, Pranava
Publicado: (2021)

Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial
por: Baos, Sarah, et al.
Publicado: (2017)

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
por: Angiolillo, Dominick J., et al.
Publicado: (2019)

Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
por: Koch, Tobias, et al.
Publicado: (2023)

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan, et al.
Publicado: (2010)

Monocytic Cells Become Less Compressible but More Deformable upon Activation
por: Ravetto, Agnese, et al.
Publicado: (2014)

The Role of Antiplatelet Therapy in Patients With MINOCA
por: Ortega-Paz, Luis, et al.
Publicado: (2022)

Pectus carinatum: When less is more
por: Martinez-Ferro, M, et al.
Publicado: (2019)

Ticagrelor as an Alternative Antiplatelet Therapy in Cardiac Patients Non-Sensitive to Aspirin
por: Khan, Hamzah, et al.
Publicado: (2020)

Aspirin/ticagrelor: Haemoperitoneum and hepatic subcapsular haematoma: 2 case reports
Publicado: (2021)

Aspirin/clopidogrel/ticagrelor: Diffuse ooze and bleeding: 2 case reports
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2020)

Reflections after TWILIGHT study: a new era in secondary prevention without aspirin?
por: Occhipinti, Giovanni, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3eht31op56aa4rebdjgaq8inga